For this annual special report, which is in its 30th year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
The amount of new drug approvals in 2015 was the FDA’s highest total since 1950 due in part to revamped pipelines, but a tough future looms as the grumblings over pricing have risen to a roar.
Just a few years after its spin-off from Abbott, Med Ad News Company of the Year AbbVie is very much back in the big pharma conversation.
Amgen has focused the company’s business and operating model through significant transformation and process improvement efforts to produce innovative medicines while generating satisfactory investor returns.
AstraZeneca continues to rely on its growth platforms to bring the company back on track, weathering patent expirations as it cultivates the pipeline with many promising products.
Bayer revamped its business model by spinning off its MaterialsScience sector into an independent company in 2015 and acquired Monsanto during 2016.
The leaders of Bristol-Myers Squibb are hoping that Opdivo and Eliquis will each generate multi-billion sales growth for years to come.
Sovaldi and Harvoni have transformed Gilead – but what’s next now that both have likely passed their peak?
GlaxoSmithKline continues to accelerate new product sales momentum and bolster the company’s pharmaceuticals, vaccines and consumer healthcare businesses.
To meet performance objectives, J&J developed a set of near-term priorities for each business segment that will allow the company to achieve long-term growth.